Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.
A new study shows all-oral direct-actin antiviral agents for hepatitis C can provide both short- and long-term economic value.
A test for hepatitis B virus should be done for patients beginning treatment with direct-acting antiviral therapy for their hepatitis C, experts advise.
Insurance arrangements for direct-acting antivirals, where hepatitis C virus patients share the burden of treatment costs, are ineffective says one researcher.
U.S. study finds those with HCV three times more likely to drink five or more drinks per day every day vs. those without HCV infections.
A real-world study confirms the effectiveness and safety of the all-oral combination of sofosbuvir plus ribavirin for treatment of hepatitis C virus GT2 infection.
Removing potential barriers to treat hepatitis C virus is yet another key component to patient access, notes lead researcher.
HCVcAg tests may cost less and improve diagnostic capacity in settings of high hepatitis C virus prevalence, according to new research.
Lead researcher says economic impact of hepatitis C virus will increase unless action is taken now.